Tutorial on Conditional Simulations With a Tumor Size‐Overall Survival Model to Support Oncology Drug Development
CPT: Pharmacometrics & Systems Pharmacology · 2025
DOI: 10.1002/psp4.70003 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, 2025. Verfasst von Sebastiaan C Goulooze und 8 weiteren Autor:innen. Beteiligte Einrichtung: LAP&P Consultants, Leiden, the Netherlands. Hauptthemen laut MEDLINE: Drug Development, Neoplasms, Antineoplastic Agents, Tumor Burden. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GSK, GlaxoSmithKline.
Abstract (Originalsprache)
The gold standard for regulatory approval in oncology is overall survival (OS). Because OS data are initially limited, early drug development decisions are often based on early efficacy endpoints, such as objective response rate and progression‐free survival. Tumor size (TS)‐OS models provide a framework to support decision‐making on potential late‐stage success based on early readouts, through leveraging TS data with limited follow‐up and treatment‐agnostic TS‐OS link functions, to predict longer‐term OS. Conditional simulations (also known as Bayesian forecasting) with TS‐OS models can be used to simulate long‐term OS outcomes for an ongoing study, conditional on the available TS and OS data at interim data cuts of the same study. This tutorial provides a comprehensive overview of the steps involved in using such conditional simulations to support better informed drug development decisions in oncology. The tutorial covers the selection of the TS‐OS framework model; applying the TS‐OS model to the interim data; performing conditional simulations; generating relevant output; as well as correct interpretation and communication of the output for decision making.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LAP&P Consultants, Leiden, the Netherlands.
- Clinical Pharmacology Modeling & Simulation, GSK, Upper Providence, Pennsylvania, USA.
- Oncology Biostatistics, GSK, Upper Providence, Pennsylvania, USA.
- Clinical Pharmacology Modeling & Simulation, GSK, Waltham, Massachusetts, USA.
- Clinical Pharmacology Modeling & Simulation, GSK, Durham, North Carolina, USA.
ORCID-Profile: Sebastiaan C Goulooze, Morris Muliaditan, Alejandro Mantero, Sandra A G Visser, Teun M Post, Chetan Rathi, Herbert Struemper
Förderung
- GSK
- GlaxoSmithKline
Zitieren
APA
Goulooze, S. C., Muliaditan, M., Franzese, R. C., Mantero, A., Visser, S. A. G., Melhem, M., Post, T. M., Rathi, C., & Struemper, H. (2025). Tutorial on Conditional Simulations With a Tumor Size‐Overall Survival Model to Support Oncology Drug Development. CPT: Pharmacometrics & Systems Pharmacology. https://doi.org/10.1002/psp4.70003
Vancouver
Goulooze SC, Muliaditan M, Franzese RC, Mantero A, Visser SAG, Melhem M, et al. Tutorial on Conditional Simulations With a Tumor Size‐Overall Survival Model to Support Oncology Drug Development. CPT: Pharmacometrics & Systems Pharmacology. 2025. doi:10.1002/psp4.70003
BibTeX
@article{Goulooze2025,
author = {Goulooze, Sebastiaan C and Muliaditan, Morris and Franzese, Richard C and Mantero, Alejandro and Visser, Sandra A G and Melhem, Murad and Post, Teun M and Rathi, Chetan and Struemper, Herbert},
title = {Tutorial on Conditional Simulations With a Tumor Size‐Overall Survival Model to Support Oncology Drug Development},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
doi = {10.1002/psp4.70003}
}
EUVIMED